{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Finerenone+Placebo", "query": { "intervention": "Finerenone Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Finerenone+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T17:28:54.983Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05640180", "title": "An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY94-8862)", "type": "DRUG" }, { "name": "Sodium-glucose cotransporter-2 inhibitors (SGLT2i)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17847, "start_date": "2022-11-23", "completion_date": "2023-12-20", "has_results": false, "last_update_posted_date": "2024-01-08", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05640180" }, { "nct_id": "NCT02545049", "title": "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Kidney Disease" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7352, "start_date": "2015-09-17", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2022-04-15", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 173, "location_summary": "Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02545049" }, { "nct_id": "NCT05196035", "title": "A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease", "Proteinuria" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 219, "start_date": "2022-03-28", "completion_date": "2027-05-10", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 10, "location_summary": "Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05196035" }, { "nct_id": "NCT05013008", "title": "An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 951, "start_date": "2021-08-18", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 13, "location_summary": "Northridge, California • Port Hueneme, California • Waterbury, Connecticut + 9 more", "locations": [ { "city": "Northridge", "state": "California" }, { "city": "Port Hueneme", "state": "California" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013008" }, { "nct_id": "NCT02540993", "title": "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5734, "start_date": "2015-09-17", "completion_date": "2020-04-14", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02540993" }, { "nct_id": "NCT05254002", "title": "A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus", "Chronic Kidney Disease" ], "interventions": [ { "name": "Finerenone (BAY94-8862 ) 10 mg", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Empagliflozin Placebo", "type": "DRUG" }, { "name": "Finerenone (BAY94-8862 ) 20 mg", "type": "DRUG" }, { "name": "Finerenone Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1664, "start_date": "2022-06-23", "completion_date": "2025-03-17", "has_results": true, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 46, "location_summary": "Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more", "locations": [ { "city": "Surprise", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05254002" }, { "nct_id": "NCT04435626", "title": "Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 6016, "start_date": "2020-09-14", "completion_date": "2024-06-14", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 107, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435626" }, { "nct_id": "NCT06059664", "title": "The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant; Complications" ], "interventions": [ { "name": "Finerenone Oral Tablet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-04-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06059664" }, { "nct_id": "NCT05047263", "title": "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-diabetic Chronic Kidney Disease" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1584, "start_date": "2021-09-21", "completion_date": "2026-02-02", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 57, "location_summary": "Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047263" }, { "nct_id": "NCT04477707", "title": "A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 206, "start_date": "2020-07-23", "completion_date": "2021-06-25", "has_results": false, "last_update_posted_date": "2022-06-29", "last_synced_at": "2026-09-03T17:28:54.983Z", "location_count": 10, "location_summary": "Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477707" } ] }